Connect Biopharma Holdings Limited

Equities

CNTB

US2075231017

Biotechnology & Medical Research

Delayed Nasdaq 02:10:13 2024-05-23 pm EDT 5-day change 1st Jan Change
1.63 USD -2.98% Intraday chart for Connect Biopharma Holdings Limited -5.23% +38.14%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Sector Update: Health Care MT
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer MT
HC Wainwright Adjusts Price Target on Connect Biopharma Holdings to $8 From $7, Maintains Buy Rating MT
Connect Biopharma Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ADRs Advance, Eco Wave Power Global AB Climbs 213.4% DJ
ADRs Advance; Connect Biopharma Climbs 19% DJ
ADRs Close Lower; Moatable Inc. Declines 33.3% DJ
ADRs End Higher; Connect Biopharma Climbs 26% DJ
ADRs End Higher; Connect Biopharma Holdings Climbs 21% DJ
HC Wainwright Starts Coverage on Connect Biopharma With Buy Rating, $7 Price Target MT
ADRs End Flat; Tuniu Climbs 16% DJ
Connect Biopharma Holdings Limited Appoints James Huang to Board of Directors CI
ADRs End With Gains; TC BioPharm Climbs 38% DJ
Transcript : Connect Biopharma Holdings Limited - Special Call
Connect Biopharma Holdings Limited Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-To-Severe Persistent Asthma CI
Simcere Signs Commercialization Deal for Sale of Dermatitis Treatment in China MT
ADRs Slump, Connect Biopharma Holdings Ltd. Declines 38.8% DJ
Transcript : Connect Biopharma Holdings Limited - Special Call
Simcere Pharmaceutical Group Limited Enters into an Exclusive License and Collaboration Agreement with Connect Biopharma Hongkong Limited in Relation to Rademikibart CI
Connect Biopharma Releases 'Positive' Stage 2 Atopic Dermatitis Trial Results; Unveils Licensing Deal; Shares Surge Premarket MT
Connect Biopharma Holdings Limited Appoints Kan Chen as Member of Compensation Committee CI
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-To-Severe Atopic Dermatitis CI
ADRs Advance; Trivago N.V. Climbs 86.6% DJ
ADRs Advance, Cellectis S.A. Climbs 172.2% DJ
Chart Connect Biopharma Holdings Limited
More charts
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company focused on improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. Its second product candidate, icanbelimod, is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). Icanbelimod is an orally available, small molecule modulator of S1P1 that is designed to reduce inflammation without killing T cells.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.68 USD
Average target price
7 USD
Spread / Average Target
+316.67%
Consensus
  1. Stock Market
  2. Equities
  3. CNTB Stock
  4. News Connect Biopharma Holdings Limited
  5. Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer